Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2017

Vandekerkhove Gillian, Todenhöfer Tilman, Annala Matti, Struss Werner J, Wong Amanda, Beja Kevin, Ritch Elie, Brahmbhatt Sonal, Volik Stanislav V, Hennenlotter Jörg, Nykter Matti, Chi Kim N, North Scott, Stenzl Arnulf, Collins Colin C, Eigl Bernhard J, Black Peter C, Wyatt Alexander W

Abstract excerpt

Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating tumor DNA (ctDNA) is established in several solid malignancies as a minimally invasive tool to profile the tumor genome in real-time, but is critically underexplored in bladder cancer.Experimental Design: We applied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-mdm2

Share to Receptor, ErbB-2

Share to Retinoblastoma Binding Proteins

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 28760909
DOI: 10.1158/1078-0432.CCR-17-1140

Genes

ERBB2
FGFR3
MDM2
TSC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.PMID 28760909Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read ↗

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Semantic proximity Read ↗

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.Semantic proximity Read ↗

Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-upSemantic proximity Read ↗

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Semantic proximity Read ↗

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assaySemantic proximity Read ↗

Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.Semantic proximity Read ↗

Integrated Plasma and Urinary Cell-free DNA Profiling Enables Noninvasive Molecular Detection from Ta to T4 Bladder CancerSemantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.Semantic proximity Read ↗

Comprehensive genomic characterization of early-stage bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.